
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Motixafortide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Motixafortide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
July 23, 2024
Lead Product(s) : Motixafortide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Motixafortide,G-CSF
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : BioLineRx
Deal Size : $279.6 million
Deal Type : Licensing Agreement
BioLineRx Entered Exclusive License Agreement with Motixafortide in Asia, Advised by MSQ Ventures
Details : Under the agreement, BioLineRx gain the rights for the development of Aphexda (motixafortide), a CXCR4 antagonist, in stem cell mobilization and pancreatic cancer, in Asia.
Product Name : Aphexda
Product Type : Peptide, Unconjugated
Upfront Cash : $29.6 million
October 31, 2023
Lead Product(s) : Motixafortide,G-CSF
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : BioLineRx
Deal Size : $279.6 million
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zimberelimab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : YuTuo (zimberelimab) is the world's first fully human anti-PD-1 monoclonal antibody in market developed by the transgenic rat platform, OmniRat, which is investigated for the treatment of metastatic cervical cancer.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 06, 2023
Lead Product(s) : Zimberelimab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : GLS-012
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GLS-012 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 07, 2023
Lead Product(s) : GLS-012
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : GLS-012
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GLS-012 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 18, 2023
Lead Product(s) : GLS-012
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : Zimberelimab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hodgkin Disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 13, 2023

Details : GLS-010 is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Uterine Cervical Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 05, 2023

Details : GLS-010 is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hodgkin Disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 26, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zimberelimab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Ligand Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zimberelimab is a fully human monoclonal antibody that belongs to a class of immuno-oncology agents known as immune checkpoint inhibitors.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 30, 2021
Lead Product(s) : Zimberelimab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Ligand Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable

Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer
Details : GLS-010 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Uterine Cervical Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 04, 2019
